<DOC>
	<DOC>NCT00505648</DOC>
	<brief_summary>Efficacy and tolerance of Tegeline® treatment in hypersensitivity syndrome. Immunological study of the T cell index phenotype and functionality in hypersensitivity syndrome.</brief_summary>
	<brief_title>Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Drug Hypersensitivity</mesh_term>
	<mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
	<criteria>Age &gt;= 18 Cutaneous and/or mucous eruption Polyadenopathy Body temperature &gt; 38°C Hematology disorders : Hypereosinophily &gt; 1.5 G/l, lymphocytosis &gt; 5G/l, atypical blood lymphocytes Consent obtained from patient Age &lt; 18 No consent obtained from patient IgV allergy Dress with very sérious visceral attack and vital diagnostic (sharp cardiac insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal insufficiency) Oral therapy or immunosuppressive therapy (Methotrexate, cyclosporine, cyclophosphamide, etc.) IgA deficiency, MCI &gt;=35 Sharp renal insufficiency before Dress with creatinaemia &lt; 60 ml/min (Cockroft)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypersensitivity</keyword>
	<keyword>Syndrome</keyword>
	<keyword>Tegeline</keyword>
</DOC>